Effect of DPP-4(dipeptidyl peptidase-4) inhibitor for coronary plaque in diabetes patients.

Trial Profile

Effect of DPP-4(dipeptidyl peptidase-4) inhibitor for coronary plaque in diabetes patients.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2014

At a glance

  • Drugs Vildagliptin (Primary) ; Glimepiride
  • Indications Diabetes mellitus; Ischaemic heart disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 09 Sep 2014 Status changed from recruiting to discontinued, according to UMIN record.
    • 09 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top